JP2018513216A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018513216A5 JP2018513216A5 JP2018505578A JP2018505578A JP2018513216A5 JP 2018513216 A5 JP2018513216 A5 JP 2018513216A5 JP 2018505578 A JP2018505578 A JP 2018505578A JP 2018505578 A JP2018505578 A JP 2018505578A JP 2018513216 A5 JP2018513216 A5 JP 2018513216A5
- Authority
- JP
- Japan
- Prior art keywords
- car
- medicine
- antigen receptor
- cells
- medicament according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 22
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 5
- 238000002347 injection Methods 0.000 claims 5
- 239000007924 injection Substances 0.000 claims 5
- 101710043956 CEACAM5 Proteins 0.000 claims 4
- 101710043948 CEACAM7 Proteins 0.000 claims 4
- 210000002767 Hepatic Artery Anatomy 0.000 claims 4
- 210000004185 Liver Anatomy 0.000 claims 4
- 102100002896 PSG2 Human genes 0.000 claims 4
- 101700004495 PSG2 Proteins 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 102100019461 CD28 Human genes 0.000 claims 3
- 101700033362 CD28 Proteins 0.000 claims 3
- 238000002583 angiography Methods 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 210000004204 Blood Vessels Anatomy 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 206010027476 Metastasis Diseases 0.000 claims 2
- 210000002966 Serum Anatomy 0.000 claims 2
- 230000001086 cytosolic Effects 0.000 claims 2
- 229940079593 drugs Drugs 0.000 claims 2
- 230000000004 hemodynamic Effects 0.000 claims 2
- 108010083359 Antigen Receptors Proteins 0.000 claims 1
- 102000006306 Antigen Receptors Human genes 0.000 claims 1
- 206010061289 Metastatic neoplasm Diseases 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000038129 antigens Human genes 0.000 claims 1
- 108091007172 antigens Proteins 0.000 claims 1
- 108091006028 chimera Proteins 0.000 claims 1
- 230000036449 good health Effects 0.000 claims 1
- 238000002513 implantation Methods 0.000 claims 1
- 230000001394 metastastic Effects 0.000 claims 1
- 230000036678 protein binding Effects 0.000 claims 1
- VWQVUPCCIRVNHF-OUBTZVSYSA-N yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 claims 1
Claims (15)
- 肝転移の治療のための医薬であって、
キメラ抗原受容体タンパク質を発現するキメラ抗原受容体Ｔ細胞（ＣＡＲ−Ｔ細胞）を含み、前記キメラ抗原受容体タンパク質は、肝臓中の転移性細胞上に発現する抗原に結合し、前記キメラ抗原受容体タンパク質は、配列番号１の配列を含む、医薬。 - 肝動脈及び近くの血管をマッピングするために血管造影を実施することに使用するための、請求項１に記載の医薬。
- 前記肝臓中に流れ込まない血管を閉塞させることに使用するための、請求項２に記載の医薬。
- ｄ
経皮的な注入中に血管造影を実施することに使用するための医薬であって、前記血管造影は、前記経皮的な注入中に肝内血行動態健常性（ｉｎｔｒａｈｅｐａｔｉｃ ｈｅｍｏｄｙｎａｍｉｃ ｉｎｔｅｇｒｉｔｙ）を監視する、請求項１〜３のいずれか１項に記載の医薬。 - 第２の治療剤をさらに含む、請求項１〜４のいずれか１項に記載の医薬。
- 前記第２の治療剤がＩＬ−２である、請求項５に記載の医薬。
- 免疫応答性細胞を含む組成物の経皮的注入の前、前記注入の間、または前記注入の後に前記第２の治療剤を投与することに使用するための、請求項６に記載の医薬。
- １週間に１回、２週間に１回、３週間に１回、または４週間に１回、前記ＣＡＲ−Ｔ細胞を含む組成物を肝動脈に経皮的に注入することに使用するための、請求項１〜４のいずれか１項に記載の医薬。
- １０８〜１０１０個のＣＡＲ−Ｔ細胞を含む組成物を肝動脈に経皮的に注入することに使用するための、請求項１〜４のいずれか１項に記載の医薬。
- 前記組成物の注入が、前記注入前の血清中のＣＥＡのレベルと比較して、血清ＣＥＡの４０％〜５０％の減少をもたらす、請求項１〜４のいずれか１項に記載の医薬。
- 肝転移の治療のための医薬であって、
キメラ抗原受容体（ＣＡＲ）タンパク質を発現するＣＡＲ−Ｔ細胞を含み、前記ＣＡＲタンパク質はＣＥＡに結合し、前記キメラ抗原受容体タンパク質は、配列番号１の配列を含む、医薬。 - 前記ＣＡＲが、Ｎ末端からＣ末端の方向に、ＣＥＡに結合するｓｃＦｖ、ＣＤ８ヒンジドメイン、ＣＤ２８細胞外ドメイン、ＣＤ２８膜貫通ドメイン、ＣＤ２８細胞質ドメイン、及びＣＤ３ゼータ細胞質ドメインを含む、請求項１１に記載の医薬。
- １０８〜１０１０個のＣＡＲ−Ｔ細胞を肝動脈に経皮的に注入することに使用するための、請求項１２に記載の医薬。
- 第２の治療剤を含む組成物をさらに含む、請求項１２に記載の医薬。
- 前記第２の治療剤がＩＬ−２またはイットリウム−９０である、請求項１４に記載の医薬。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562147793P | 2015-04-15 | 2015-04-15 | |
| US62/147,793 | 2015-04-15 | ||
| PCT/US2016/027582 WO2016168493A1 (en) | 2015-04-15 | 2016-04-14 | Hepatic arterial infusion of car-t cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018513216A JP2018513216A (ja) | 2018-05-24 |
| JP2018513216A5 true JP2018513216A5 (ja) | 2019-05-23 |
Family
ID=57126310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018505578A Pending JP2018513216A (ja) | 2015-04-15 | 2016-04-14 | Ｃａｒ−ｔ細胞の肝動脈注入 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10471098B2 (ja) |
| EP (1) | EP3283083A4 (ja) |
| JP (1) | JP2018513216A (ja) |
| KR (1) | KR20180021364A (ja) |
| CN (1) | CN108135937A (ja) |
| AR (1) | AR104296A1 (ja) |
| AU (1) | AU2016248090A1 (ja) |
| CA (1) | CA2982603A1 (ja) |
| HK (1) | HK1251179A1 (ja) |
| IL (1) | IL255005A0 (ja) |
| MX (1) | MX2017013247A (ja) |
| TW (1) | TWI719019B (ja) |
| WO (1) | WO2016168493A1 (ja) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016210133A1 (en) | 2015-06-24 | 2016-12-29 | The Regents Of The Universtiy Of Michigan | Histotripsy therapy systems and methods for the treatment of brain tissue |
| CN107056952A (zh) * | 2017-05-10 | 2017-08-18 | 常州市第人民医院 | Cea.car‑t及其制备与应用 |
| WO2019030757A1 (en) * | 2017-08-09 | 2019-02-14 | Ctg Pharma Ltd. | CHIMERIC ANTIGEN RECEPTOR FOR HER2 / NEU AND LYMPHOCYTES T THE EXPRESSANT |
| EP3704156A1 (en) * | 2017-11-03 | 2020-09-09 | Sorrento Therapeutics, Inc. | Cd38-directed chimeric antigen receptor constructs |
| SG11202003956TA (en) | 2017-11-30 | 2020-06-29 | Singapore Health Serv Pte Ltd | A system and method for classifying cancer patients into appropriate cancer treatment groups and compounds for treating the patient |
| WO2019173837A1 (en) * | 2018-03-09 | 2019-09-12 | Sorrento Therapeutics, Inc. | Dimeric antigen receptors (dar) |
| SG11202101014XA (en) * | 2018-08-02 | 2021-02-25 | Kite Pharma Inc | Chimeric antigen receptor therapy t cell expansion kinetics and uses thereof |
| US20210346430A9 (en) * | 2018-08-26 | 2021-11-11 | Oaiscell Biotechnologies | Method for treating glioblastoma |
| US11813484B2 (en) | 2018-11-28 | 2023-11-14 | Histosonics, Inc. | Histotripsy systems and methods |
| EP3799881A1 (en) | 2019-10-04 | 2021-04-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Single domain antibodies specifically binding globo - series glycans |
| MX2022006288A (es) * | 2019-11-25 | 2022-06-08 | Univ Kyoto | Banco de celulas maestras de celulas t. |
| EP4096782A4 (en) * | 2020-01-28 | 2024-02-14 | Univ Michigan Regents | SYSTEMS AND METHODS FOR IMMUNOSENSITIZATION BY HISTOTRIPSY |
| JP2023542988A (ja) * | 2020-09-22 | 2023-10-12 | トリサルース・ライフ・サイエンシズ・インコーポレイテッド | トール様受容体アゴニストを使用したがん治療 |
| JP2024500847A (ja) | 2020-12-18 | 2024-01-10 | センチュリー セラピューティクス，インコーポレイテッド | 適合可能な受容体特異性を有するキメラ抗原受容体システム |
| US20240066125A1 (en) * | 2021-02-09 | 2024-02-29 | Obi Pharma, Inc. | Globo series antigens-binding chimeric antigen receptors and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020165360A1 (en) | 2000-11-30 | 2002-11-07 | Junghans Richard P. | Chimeric effector cell receptors against carcinoembryonic antigen |
| US9206440B2 (en) * | 2009-01-23 | 2015-12-08 | Roger Williams Hospital | Viral vectors encoding multiple highly homologus non-viral polypeptides and the use of same |
| CN106074601A (zh) * | 2011-03-23 | 2016-11-09 | 弗雷德哈钦森癌症研究中心 | 用于细胞免疫治疗的方法和组合物 |
| CN103483452B (zh) * | 2012-06-12 | 2021-08-13 | 上海细胞治疗集团有限公司 | 双信号独立的嵌合抗原受体及其用途 |
| CN112430580A (zh) | 2012-10-02 | 2021-03-02 | 纪念斯隆-凯特琳癌症中心 | 用于免疫疗法的组合物和方法 |
| KR20210108497A (ko) | 2013-02-26 | 2021-09-02 | 메모리얼 슬로안 케터링 캔서 센터 | 면역치료용 조성물 및 방법 |
-
2016
- 2016-04-14 JP JP2018505578A patent/JP2018513216A/ja active Pending
- 2016-04-14 TW TW105111666A patent/TWI719019B/zh not_active IP Right Cessation
- 2016-04-14 KR KR1020177033070A patent/KR20180021364A/ko unknown
- 2016-04-14 WO PCT/US2016/027582 patent/WO2016168493A1/en active Application Filing
- 2016-04-14 AU AU2016248090A patent/AU2016248090A1/en not_active Abandoned
- 2016-04-14 CA CA2982603A patent/CA2982603A1/en not_active Abandoned
- 2016-04-14 MX MX2017013247A patent/MX2017013247A/es unknown
- 2016-04-14 US US15/099,370 patent/US10471098B2/en not_active Expired - Fee Related
- 2016-04-14 EP EP16780765.0A patent/EP3283083A4/en not_active Withdrawn
- 2016-04-14 CN CN201680035380.XA patent/CN108135937A/zh active Pending
- 2016-04-15 AR ARP160101045A patent/AR104296A1/es unknown
-
2017
- 2017-10-15 IL IL255005A patent/IL255005A0/en unknown
-
2018
- 2018-08-21 HK HK18110746.6A patent/HK1251179A1/zh unknown
-
2019
- 2019-10-09 US US16/597,798 patent/US20200138863A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018513216A5 (ja) | ||
| Pento | Monoclonal antibodies for the treatment of cancer | |
| Alnefaie et al. | Chimeric antigen receptor T-cells: an overview of concepts, applications, limitations, and proposed solutions | |
| Whiteside et al. | Emerging opportunities and challenges in cancer immunotherapy | |
| Li et al. | Drugs for autoimmune inflammatory diseases: from small molecule compounds to anti-TNF biologics | |
| Tai et al. | B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma | |
| ES2734190T3 (es) | Receptores de linfocitos T | |
| EP2990416B1 (en) | Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders | |
| JP2017509342A5 (ja) | ||
| Ma et al. | Advanced generation anti‐prostate specific membrane antigen designer T Cells for prostate cancer immunotherapy | |
| JP2017537622A5 (ja) | ||
| Gohil et al. | An ROR1 bi-specific T-cell engager provides effective targeting and cytotoxicity against a range of solid tumors | |
| JP2017537627A5 (ja) | ||
| JP2018509163A5 (ja) | ||
| IL292650A (en) | Chimeric antigen receptor T cells target il13ra2 | |
| JP2018502060A5 (ja) | ||
| JP2017513478A5 (ja) | ||
| JP2016520074A5 (ja) | ||
| JP2019513777A5 (ja) | ||
| RU2016143155A (ru) | Cd33-специфические химерные антигенные рецепторы для иммунотерапии рака | |
| JP2020517259A5 (ja) | ||
| JP2017507936A5 (ja) | ||
| Liu et al. | Split chimeric antigen receptor-modified T cells targeting glypican-3 suppress hepatocellular carcinoma growth with reduced cytokine release | |
| JP2020517658A5 (ja) | ||
| Snook et al. | Selective antigen‐specific CD4+ T‐cell, but not CD8+ T‐or B‐cell, tolerance corrupts cancer immunotherapy |